We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. OK, I agree | Cookies Policy



Utipro® Plus Launched In Israel

We are pleased to announce the launch in Israel of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is distributed by our long term partner Lapidot. Utipro® Plus is a medical device intended for the control and prevention of urinary tract infections produced by pathogens such as E.coli and other gram (-) bacteria normally involved in the etiology of urological infections. Utipro® Plus has been presented to HCP and available as capsules for oral administration in pharmacies all across the Israeli territory since Q4 2017. Utipro® Plus is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0373, Noventure SL)

Read more

Congresses: Noventure presents its new IBS product Gelsectan® at the 25th UEG week in Barcelona, Spain.

Noventure has participated in the recent 25th UEG week, one of the world’s most important meetings in the field of gastroenterology, which attracts clinicians and basic scientists from all over the world. For the first time the “Gelsectan®” brand was presented at the Noventure stand, now that the medical device is available in its first market, Spain. Gelsectan® belongs to a new class of products defined as “mucosal protectors”, which help restore the normal function of the epithelial barrier in the gut. It is intended to relieve and prevent IBS symptoms such as chronic or relapsing diarrhoea, pain and bloating.

Read more

Tasectan® Duo launched in Austria

We are pleased to announce the launch of Tasectan® Duo in Austria by our partner company Montavit. This will be Tasectan® Duo´s second market, after the successful introduction in Italy by Angelini. Tasectan Duo ® is the first combination of gelatin tannate and inactivated bacteria, and can be used to re-establish the physiological functions of the gut barrier, as well as to prevent dysbiosis. It is intended for prolonged diarrhea (lasting between 1 - 2 weeks) or for the prevention and management of diarrhea associated with antibiotic treatment, and is expected to capture part of the market space of probiotics used for diarrhea.

Read more

Let's meet in..

2019, Nov 05

CPhI 2019

Read more

2019, Nov 25

euroPLX 71

Read more

2019, Nov 28

PharmaVenue November 2019

Read more